Endovascular Therapies for Type B Aortic Dissection.

Cardiovasc Hematol Disord Drug Targets

Department of Internal Medicine, Department of Cardiovascular Medicine, Texas Tech University, El Paso, TX, USA.

Published: February 2022

Aortic dissection is a life-threatening condition resulting from a tear in the intimal layer of the aorta, requiring emergent diagnosis and prompt multi-disciplinary management strategy for best patient outcomes. While type A dissection involving ascending aorta is best managed surgically due to high early mortality, Type B Aortic Dissection (TBAD) involving descending aorta generally has better outcomes with conservative management and medical therapy as a primary strategy is favored. However, there has been a recent paradigm shift in the management of TBAD due to late aneurysmal degeneration of TBAD, increasing morbidity and mortality in the long term. Late surgical intervention can be prevented by early endovascular intervention when combined with optimal medical therapy. In this narrative review, we explore available literature on different endovascular therapies for TBAD in different populations of patients.

Download full-text PDF

Source
http://dx.doi.org/10.2174/1871529X21666210924141446DOI Listing

Publication Analysis

Top Keywords

aortic dissection
12
endovascular therapies
8
type aortic
8
medical therapy
8
therapies type
4
dissection
4
dissection aortic
4
dissection life-threatening
4
life-threatening condition
4
condition tear
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!